Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07158905 · ClinicalTrials.gov registry record · Phase 1
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
A Phase 1 study, sponsored by Institute for Molecular Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT07158905: Recruiting Phase 1 study, sponsored by Institute for Molecular Medicine.
NCT07158905 is a Phase 1 study that is actively recruiting participants, run by Institute for Molecular Medicine. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07158905, a Phase 1 study, is actively recruiting participants, sponsored by Institute for Molecular Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose-escalating trial to evaluate the safety, tolerability, and immune response of AV-1980R, an investigational vaccine targeting tau protein, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65-80 with biomarker evidence of early Alzheimer's disease will be enrolled into three ascending dose cohorts. The study is designed as a secondary prevention trial to test whether therapeutic immunization at the preclinical stage is safe, induces an immune response, and, exploratorily, may favorably affect biomarkers associated with disease progression.
Primary Outcome
Number of participants who experience one or more treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs), summarized by severity and relationship to study intervention.
Interventions
- OTHER Placebo
- BIOLOGICAL AV-1980R 20 µg
- BIOLOGICAL AV-1980R 60 µg
- BIOLOGICAL AV-1980R 180 µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-06-23 |
| Est. Completion | 2029-10-15 |
| Phase | Phase 1 |
What NCT07158905 shows while recruiting
NCT07158905 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07158905 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07158905 about?
NCT07158905 is a clinical study titled "AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)". This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose-escalating trial to evaluate the safety, tolerability, and immune response of AV-1980R, an investigational vaccine targeting tau protein, in participants with preclinical Alzheimer's disease. Up to 48 cogniti...
What is the current status of trial NCT07158905?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-06-23. Estimated completion is 2029-10-15.
What interventions are being tested in trial NCT07158905?
The interventions under investigation include: Placebo (OTHER), AV-1980R 20 µg (BIOLOGICAL), AV-1980R 60 µg (BIOLOGICAL), AV-1980R 180 µg (BIOLOGICAL).
Who is sponsoring clinical trial NCT07158905?
This trial is sponsored by Institute for Molecular Medicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07158905's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI